公司本次通过药品 GMP 符合性检查，表明公司产品生产质量管理符合 GMP 要求，将有利于公司继续 保持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。本次药品GMP符合性检查 结果不会对公司业绩产生重大影响。 格隆汇1月7日丨华润双鹤(600062.SH)公布，近日，公司全资子公司北京万辉双鹤药业有限责任公司收 到北京市药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号：京药监药 GMP[2025]020140)。 ...

近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公 司北京万辉双鹤药业有限责任公司收到北京市药品监督管理局颁发 的《药品 GMP 符合性检查告知书》(编号：京药监药 GMP[2025]020140)， 现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：北京万辉双鹤药业有限责任公司 证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－003 华润双鹤药业股份有限公司 关于全资子公司北京万辉双鹤药业有限责任公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 二、本次检查所涉生产线及产品情况 生产车间生产线：综合制造车间，软胶囊剂生产线 设计产能：30,000 万粒/年 代表品种：阿法骨化醇软胶囊 检查地址：北京市门头沟区石龙经济开发区上园路 1 号 检查范围及相关车间、生产线： 委托华润双鹤药业股份有限公司(北京市朝阳区双桥东路 2 号)综 合制造车间软胶囊剂生产线生产软胶囊剂阿法骨化醇软胶囊(国药准 字 H20255672)。 检查时间：2025 年 11 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2026-002 华润双鹤药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 股东会召开日期：2026年1月23日 本次股东会采用的网络投票系统：上海证券交易所股东会网络 投票系统 一、召开会议的基本情况 网络投票起止时间：自2026 年 1 月 23 日 至2026 年 1 月 23 日 (一) 股东会类型和届次 2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网 络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2026 年 1 月 23 日 10 点 00 分 召开地点：北京市朝阳区锐创国际中心 A 座 9 层会议室 (五) 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东会召开当日的交易时间段， ...

华润双鹤公告，全资子公司北京万辉双鹤药业有限责任公司收到北京市药品监督管理局颁发的《药品 GMP符合性检查告知书》。检查范围为华润双鹤药业股份有限公司综合制造车间软胶囊剂生产线生产 软胶囊剂阿法骨化醇软胶囊。检查时间2025年11月26日至2025年11月28日，结论为符合《药品生产质量 管理规范(2010年修订)》和附录要求。该检查项目是在原有厂房、设备情况下的检查，未投入资金。 ...

Core Insights - The article discusses the recent launch of various government-guided funds aimed at supporting early-stage and innovative companies, particularly in strategic emerging industries and hard technology sectors [7][8][9]. Government-Backed Funds - The National Venture Capital Guidance Fund was officially launched on December 26, with a fiscal contribution of 100 billion yuan, aiming to attract social capital to form a total fund size of 1 trillion yuan [7]. - The fund will focus 70% of its investments on seed and early-stage companies, with individual investments capped at 50 million yuan and a long-term duration of 20 years [7]. - The Guangdong-Hong Kong-Macao Greater Bay Area Fund has been established in Shenzhen with a target size of 50.45 billion yuan, emphasizing early and small investments in strategic emerging industries [8]. - The Sichuan Social Security Science and Technology Fund has signed agreements for an initial scale of 20 billion yuan, focusing on key technology breakthroughs and industrialization [9]. - The Hubei Social Security Science and Technology Fund has also been established with an initial scale of 20 billion yuan, targeting industries such as optoelectronics and automotive manufacturing [9]. Market-Driven Funds - The Oriental Jiafu National SME Development Sub-Fund has completed its first closing at 1.6 billion yuan, with a target total size of 2 billion yuan, focusing on advanced manufacturing and life sciences [16]. - Shengshi Investment has successfully established the first S Fund restructuring fund in China, exceeding 600 million yuan, aimed at providing innovative solutions for S Fund exits [17]. - The Deep Industry Group has set up a 500 million yuan biopharmaceutical industry fund, focusing on strategic emerging industries [17]. Specific Fund Initiatives - The Jiangsu Changdian Technology Co., Ltd. has invested 403.8 million yuan in a private fund with a total size of 1.346 billion yuan, focusing on semiconductor manufacturing [20]. - The Guangdong Wenkai Green Technology Co., Ltd. is participating in a 500 million yuan fund that targets new energy and new materials [21]. - The Ningbo Chip Innovation Fund has been established with a total size of 1 billion yuan, focusing on semiconductor and intelligent manufacturing sectors [18].

Core Viewpoint - Yunnan Kun Pharmaceutical Group has undergone significant management changes, with a new chairman and president appointed as the company aims to deepen its integration with China Resources Sanjiu and focus on the "healthy aging" sector [1][2]. Management Changes - The company announced the resignation of Chairman Wu Wendo, President Yan Wei, and Vice President Li Lichun, with Yu Xiang appointed as the new chairman and Zhong Jiang as the new president [1][2]. - Yu Xiang, aged 45, has extensive experience in various leadership roles within China Resources Sanjiu, while Zhong Jiang, aged 50, has held significant positions in financial management within the company [2]. Business Performance - Kun Pharmaceutical Group's overall performance has shown a downward trend, with a revenue decline in 2024 and a net profit increase. In 2025, the first three quarters also saw revenue and net profit declines, with a significant loss in the third quarter [3]. - In 2024, the company reported a revenue of 8.4 billion yuan, a decrease of 0.34% year-on-year, while net profit reached 648 million yuan, an increase of 19.86% [3]. - For the first three quarters of 2025, revenue was 4.751 billion yuan, down 18.08%, and net profit was 269 million yuan, down 39.42% [3]. Strategic Focus - The company aims to leverage its 70 years of drug research tradition and global marketing network to become a leader in the "silver health industry" and chronic disease management [1][4]. - Future development will focus on three core areas: cardiovascular products centered around Xuesaitong, emotional health products based on Shugan Granules, and products for mental health and pain management [4].

Core Viewpoint - Kunming Pharmaceutical Group has undergone a significant leadership change, with a complete overhaul of its core decision-making and operational teams, aiming to address recent performance challenges and adapt to external market pressures [1][2][3][4] Leadership Changes - Yu Xiang has been appointed as the new chairman, with a term lasting until January 22, 2028, succeeding Wu Wendo, who will remain on the board [1] - The new president, Zhong Jiang, has been appointed alongside Yu Xiang, with both leaders coming from the China Resources system, indicating a strategic shift in management [2][3] - Former president Yan Wei will transition to the role of vice chairman and board member, while former vice president Li Lichun will no longer hold any positions within the company [2] Financial Performance - Kunming Pharmaceutical Group has faced significant financial pressure, with a reported revenue of 4.751 billion yuan for the first three quarters of 2025, marking an 18.08% year-on-year decline [3] - The net profit attributable to shareholders decreased by 39.42% to 269 million yuan, while the net profit after deducting non-recurring items fell by 59.52% [3] - The company's accounts receivable have increased dramatically, rising from 1.358 billion yuan in mid-2020 to 3.25 billion yuan in mid-2025, a cumulative increase of 139.32% [3] Business Challenges - The primary revenue source, the Xuesaitong series, which accounts for approximately 40% of total revenue, is under pressure from price suppression due to centralized procurement policies, despite showing signs of recovery [4] - The premium traditional Chinese medicine segment, making up about 30% of revenue, is currently undergoing brand upgrades and channel restructuring, lacking stable growth momentum [4] - The new leadership team is expected to integrate resources and implement strategies to gradually restore the company's performance amidst these challenges [4]

Core Viewpoint - The recent personnel adjustments within the China Resources pharmaceutical sector reflect a strategic response to industry changes, focusing on enhancing operational efficiency and innovation capabilities in a transforming market environment [2][7]. Group 1: Personnel Changes - The legal representative of China Resources Pharmaceutical Commercial Group has been changed from Wu Jianjun to Guo Ting, marking a significant leadership shift within the company [1]. - Guo Ting's extensive experience within the China Resources system, including roles in key pharmaceutical companies, positions him to drive strategic alignment across the pharmaceutical distribution and diagnostic services sectors [3]. - Yao Donghan has been elected as an employee director of China Resources Double Crane, bringing valuable human resources management experience to support the company's organizational integration and innovation transformation [2][5]. Group 2: Strategic Adjustments - The governance structure of China Resources Pharmaceutical Commercial has been optimized, with the supervisory board being dissolved and its powers transferred to the audit committee, indicating a shift towards a more professional governance model [3]. - The company has issued 3 billion yuan in medium-term notes at a 2.19% interest rate to fund digital warehouse construction and hospital delivery network upgrades, demonstrating a commitment to enhancing operational capabilities [4]. - China Resources Double Crane has established a 500 million yuan biopharmaceutical industry fund to focus on synthetic biology and innovative drugs, aiming to create new growth avenues amid declining revenue and profit [5]. Group 3: Market Context and Industry Trends - The personnel changes occur during a period of significant policy and market transformation in the pharmaceutical industry, with new procurement policies and health insurance directories reshaping the competitive landscape [7]. - The industry is transitioning from price competition to a focus on research and quality, as indicated by the implementation of the 11th national procurement batch aimed at stabilizing clinical quality [7]. - The adjustments within China Resources are seen as a proactive adaptation to these changes, with a focus on enhancing efficiency in pharmaceutical commerce, driving innovation in chemical drugs, and strengthening brand and standards in traditional Chinese medicine [7][8].

证券代码：600062 证券简称：华润双鹤 公告编号：临 2026-001 华润双鹤药业股份有限公司 关于参与设立华润医药产业投资基金二期 完成基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 投资标的名称 | 华润(成都)医药产业股权投资基金合伙企业(有限合 | | | | --- | --- | --- | --- | | | | 伙) | | | 投资金额(万元) | | 4,000 | | | 投资进展阶段 | √进展 | 完成 终止 | 交易要素变更 | | 特别风险提示 | 1、该基金采取分步出资方式，如各有限合伙人未能 | | | | | 按执行事务合伙人通知的金额和比例履行出资义 | | | | | 务，则可能影响基金的后续募集以及对外投资计划 | | | | | 的实施； | | | | | 2、基金具有投资周期长、流动性较低的特点，在投 | | | | | 资运作过程中将受到宏观经济、行业周期、政策法 | | | | | 规等多种因素影响，可能面临投资收益不达预期甚 ...

Group 1 - The establishment of the "China Resources Double Crane Biopharmaceutical Industry Fund" with a scale of 500 million yuan focuses on key technologies and high-tech achievement transformation projects in synthetic biology and related fields [1] - This fund is the first industry fund of China Resources Group dedicated to synthetic biology, aligning with the group's strategic initiative in emerging industries [1][3] - The company aims to create a second growth curve through synthetic biology, promoting significant development during the 14th Five-Year Plan period [1][3] Group 2 - China Resources Double Crane has over 80 years of experience in the pharmaceutical industry and operates 24 subsidiaries with approximately 13,000 employees, achieving annual sales exceeding 10 billion yuan [3] - The company has set two strategic goals for the 14th Five-Year Plan: to establish its core chemical drug business as "China's leading prescription drug brand" and to leverage synthetic biology technology for new growth [3] - The company’s subsidiary, Shenzhou Biotechnology, is a key platform for the industrialization of synthetic biology, with its core product, coenzyme Q10, holding the second-largest global market share [3] Group 3 - Synthetic biology is leading a global biotechnological revolution with vast market potential across various sectors, including food, healthcare, biomaterials, green agriculture, and personal care [4] - The fund will complement the company's external mergers and acquisitions, facilitating early-stage project innovation and integration with invested companies in technology, production, and market aspects [4] - The collaboration between China Resources Double Crane and the Hohhot municipal government will enhance the competitiveness of the synthetic biology industry, leveraging local resource advantages for large-scale fermentation production [4]